A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Betrixaban in Pediatric Patients
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Betrixaban (Primary)
- Indications Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Portola Pharmaceuticals
- 23 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.
- 15 Mar 2018 Status changed from not yet recruiting to recruiting.
- 15 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Feb 2018.